Latest news with #Granules
The Hindu
6 days ago
- Business
- The Hindu
Granules Q1 net dips 16% to ₹112 crore, revenue up 3% as North America drives sales
Granules India's consolidated net profit for the quarter ended June declined more than 16% to ₹112.6 crore from the ₹134.6 crore a year earlier. The lower net profit came on a nearly 3% increase in total revenue to ₹1,210.1 crore (₹1,179.8 crore). Sales growth was largely driven by North America. The decline in net profit was on account of exceptional items mainly expenses related to ongoing litigation settlements, the company said. On a sequential basis, the net profit was 26% lower and total revenue 1% higher. Granules shares on Tuesday closed 3.17% higher at ₹455 apiece on the BSE. Region wise revenue split showed sales in the all important North America market increased 7% to ₹929.7 crore (₹870 crore), while it was 12% higher in Europe at ₹167.3 crore (₹149.3 crore). In the Rest of World market, sales slumped 30% at ₹113.1 crore (₹160.6 crore), which the company said was primarily because of pharmaceutical formulation intermediate (PFI) supply backlog from the Gagillapur manufacturing facility, near Hyderabad, to LATAM market. According to revenue split segment wise, contribution of active pharmaceutical ingredients segment for the paracetamol maker was 14% lower at ₹162.7 crore (₹189 crore); finished dosage marginally higher at ₹898.9 crore (₹891.2 crore); and PFI 20% more at ₹119.4 crore (₹99.7 crore). 'We delivered healthy cash flow from operations of Rs.280.6 crore this quarter and made good progress on the Gagillapur remediation programme. With our near-term formulations growth trajectory set to resume and the integration of Senn Chemicals through the Ascelis platform in the fast-growing CDMO sector, we are well-positioned for sustainable long-term growth,'CMD Krishna Prasad Chigurupati said.
The Hindu
09-07-2025
- Health
- The Hindu
Granules recalling 33,000 bottles of hypertension drug in U.S.
Granules is recalling more than 33,000 bottles of hypertension drug Metoprolol Succinate Extended-Release Tablets, USP, 25 mg, in the U.S. market. It is a voluntary, firm-initiated recall on account of failed dissolution specifications. The product failed to meet dissolution acceptance criteria in the stability studies at the 6th month, the U.S. Food and Drug Administration (U.S. FDA) said in its latest enforcement report. Granules Pharmaceuticals Inc is recalling 27,648 100-count bottles and 5,376 500-count bottles of the drug manufactured by Granules India, Hyderabad.
Time of India
28-05-2025
- Business
- Time of India
Granules FY25 PAT up 24% despite Gagillapur plant productivity woes
Granules FY25 PAT up 24% despite Gagillapur plant productivity woes HYDERABAD: Granules India Ltd posted a 17 per cent rise in consolidated profit after tax (PAT) for the fourth quarter ended March 31, 2025, at Rs 152 crore compared to Rs 130 crore in the same period of the last financial year. This was on a marginal 2 per-cent increase in consolidated revenue from operations at Rs 1197 crore in Q4FY25 from Rs 1176 crore in Q4FY24. However, for the financial year 2024-25, the company recorded a 24 per-cent jump in consolidated PAT at Rs 501.5 crore compared to Rs 405 crore, despite a 1 per-cent decline in revenue from operations at Rs 4482 crore from Rs 4506 crore in FY24. The company said it witnessed a sustained increase in formulations share despite the slowdown in productivity of its Gagillapur facility, where currently US FDA remediation activities are ongoing after inspectors flagged major violations of good manufacturing practices. Granules stated that while the share of revenues from the North American market rose to 79 per-cent in Q4FY25 from 70 per-cent in Q4FY24, the total share of finished dosages in revenues stood at 77 per-cent, and that of active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI) was at 12 per-cent and 10 per-cent, respectively. Granules India Ltd Chairman & Managing Director Dr Krishna Prasad Chigurupati said that although the company paused production at Gagillapur in September 2024 for over a month to reassess the risks and undertake the necessary USFDA remediation activities, the company achieved a formulations growth of 18 per-cent. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Artificial Intelligence and Machine Learning For Working Professionals. BITS Pilani WILP Apply Now Undo 'The productivity of the Gagillapur facility was lower in H2 FY25 with ongoing remediation activities. Our strong financial performance reflects the success of our strategic initiatives, particularly our focus on enhancing our product mix by prioritising high-margin offerings and expanding our portfolio of non-legacy molecules. This reflects the strength and adaptability of our business model,' he said. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
13-05-2025
- Business
- Time of India
Pharma stocks rally up to 4%, but will Trump order really have minimal impact?
Shares of pharmaceutical companies rallied up to 4% on Tuesday as investors expect that US President Donald Trump 's executive order will have minimal impact on US generics. Dr Reddy's shares were up around 4% while Granules , Glenmark , Lupin , Divi's Lab , and Aurobindo Pharma were trading around 3% higher. Nifty Pharma index itself rose around 2% even when Nifty fell around 0.5% amid profit-booking post Monday's rally, which saw the benchmark indices making the sharpest single-day gain in the last 4 years. "As far as the impact on Indian pharma companies is concerned, we foresee very limited impact. Based on our interaction with companies, the generics pricing spread is thin across developed nations, and hence, the scope of reduction in prices is expected to be limited on the US generics portfolio," brokerage Motilal Oswal said. Trump's order says that the drug prices in the US should be aligned to the prices in other developed countries. Trump intends to take action against pharmaceutical manufacturers charging higher prices to Americans while providing steep discounts to other wealthy nations but analysts say there is uncertainty on how successfully the executive order is eventually implemented. An earlier attempt by the Trump 1 administration in 2020 to implement a similar order for lowering pricing was defeated in various courts "The order is more inclined toward innovator pharma companies, which might be having pricing disparity on medicines sold in the US and other developed nations," Motilal said, adding that it estimates a very limited impact of the executive order on US generics. Nomura, however, warned that If the executive order is implemented, it will have a negative impact on branded and specialty drug sales. "In our coverage universe, Sun Pharma has the largest exposure to branded sales in the US. We estimate that US specialty sales are at ~USD1036mn (FY25F) for Sun Pharma. The largest product Ilumya (FY25F US sales of ~USD570mn) is largely supported through Medicare Part B, which possibly accounts for 50%+ of the sales of the company, in our assessment. The listed price of Ilumya in the US is ~4x that in other developed countries, in our view. Therefore, the implementation of lower pricing can have a significant negative impact on revenues and earnings, in our view," Nomura said. As generics are priced at only a modest discount (~30-40%) to the brand prices, the brokerage firm said it is not likely to have a negative impact on typical commoditized generics with more than five players in the market.
